Position in EXEL
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$854,672
+$571,341 QoQ
Shares Held
15,708
+137.8% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#355
of 751 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Vise Technologies, Inc. holds $19,918,588 across 31 Biotechnology names. EXEL ranks #4 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,882 | $3,915,225 | |
| 2 | RPRX |
Royalty Pharma plc
|
23,958 | $1,343,325 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,142 | $1,335,622 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
15,708 | $854,672 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
9,366 | $814,373 | |
| 6 | INCY |
Incyte Corp
|
7,156 | $811,204 | |
| 7 | ARGX |
Argenx SE
|
834 | $773,760 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
9,499 | $743,486 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $854,672 | 15,708 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $283,331 | 6,606 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $289,540 | 6,606 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $224,093 | 5,426 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $293,396 | 6,656 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||